Global Primary Biliary Cholangitis Market to 2030 – Insight, Epidemiology and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Primary Biliary Cholangitis – Market Insight, Epidemiology and Market Forecast 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the primary biliary cholangitis (PBC), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Primary biliary cholangitis market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Primary biliary cholangitis symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Primary biliary cholangitis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Key Findings

The diagnosed prevalent cases of PBC is increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted PBC symptoms epidemiology segmented as the Total Diagnosed Prevalent cases of Primary biliary cholangitis (PBC), Gender-specific cases of Primary biliary cholangitis (PBC), and Age-specific cases of Primary biliary cholangitis (PBC). The report includes the prevalent scenario of PBC symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Primary biliary cholangitis (PBC) Epidemiology

The epidemiology segment also provides the PBC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent cases of Primary biliary cholangitis (PBC) associated in 7MM countries was 253,146 in 2020.

Primary biliary cholangitis (PBC) Drug Chapters

The drug chapter segment of the primary biliary cholangitis (PBC) report encloses the detailed analysis of PBC early-stage (Phase- II, III) pipeline drugs. It also helps understand the PBC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

The United States Market Outlook

This section provides the total PBC market size and market size by therapies in the United States.

The United States accounts for the largest market size of PBC in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total PBC market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total PBC market Size and market Size by therapies in Japan are also mentioned.

Scope of the Report

• The report covers the descriptive overview of Primary biliary cholangitis (PBC), explaining its causes, signs and symptoms, physiology, and currently available therapies
• Comprehensive insight has been provided into the Primary biliary cholangitis (PBC) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Primary biliary cholangitis (PBC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the primary biliary cholangitis (PBC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary biliary cholangitis (PBC) market

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the Primary biliary cholangitis (PBC) market
• To understand the future market competition in the primary biliary cholangitis (PBC) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Primary biliary cholangitis (PBC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Primary biliary cholangitis (PBC) market
• To understand the future market competition in the primary biliary cholangitis (PBC) market

Companies Mentioned

• Intercept Pharmaceuticals
• CymaBay Therapeutics
• Genfit
• Genkyotex SA
• Zydus Cadila
• Cara Therapeutics
• HighTide Therapeutics
• Albireo
• GlaxoSmithKline

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1246qh

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900